

21 June 2021

Charnwood Molecular acquires Aurelia Bioscience

[Synova](#) portfolio company, [Charnwood Molecular](#), a leading UK-based pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, is pleased to announce the acquisition of biosciences specialist, [Aurelia Bioscience](#).

The sector-leading expertise and technology development within Aurelia Bioscience will further expand Charnwood's capabilities in the provision of world-class integrated drug discovery and development services. Charnwood is already a leading provider of medicinal and scale-up chemical development to the life sciences industry with a global customer base from biotech to large pharma. Aurelia will bring biology capabilities into the group allowing it to deliver holistic, integrated pre-clinical drug discovery programmes for its clients.

This acquisition follows the announcement in April this year when Charnwood committed to quadrupling its physical capacity through investment in state-of-the-art facilities at the Charnwood Campus Science Innovation and Technology Park in Loughborough. These market-leading laboratories will provide a gold-standard platform, enhancing the combined group's ability to deliver exceptional services to its clients and supporting further growth in Charnwood's team and capabilities.

CEO of Charnwood Molecular, Steve Allin, commented: *"We are proud to welcome the Aurelia Bioscience team into our company. Gary Allenby, Kathy Dodgson and their team have built an enviable reputation for scientific rigour and excellence - values that are deeply rooted in our own business culture - and this acquisition represents another key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector."*

Zac Tsai, Partner at Synova and Director of Charnwood Molecular, noted: *"The acquisition of Aurelia represents another exciting milestone in Charnwood Molecular's journey and Synova continues to support the team's ambitious strategy of scale and service line expansion through a combination of organic investment and M&A."*

ENDS

1/2

NOTES:

1. **Synova** is recognised across the industry as one of Europe's most innovative growth investors, investing in companies typically valued between £30m and £150m. We invest across a handful of core sectors, including **Technology**, **Financial Services**, **Business Services**, and **Health & Education**, where we have deep investment and operational expertise
2. Synova has generated industry-leading returns, which has been reflected in being awarded '*Private Equity House of the Year*' four times in the past seven years. Synova was recently listed as one of the '*Most Consistent Top Performing Buyout Fund Managers*' globally by *Preqin*. Synova is the only private equity firm in the UK, and one of only two in Europe, with a number one *Preqin* ranking with all of its applicable funds ranked in the top quartile, placing Synova as one of the Top 9 best performers globally
3. Synova has completed a number of new investments and successful exits across the **Health** sector with the sale of **4Ways** to ECI Partners (6.0x invested capital) and **Kinapse** to HgCapital (16.1x invested capital); and investments in **Charnwood Molecular** (drug discovery services), **PreventX** (online-led sexual health testing and diagnostics), **Clyde Munro** (Scottish dental consolidation platform) and **Oakland Care** (premium residential elderly care)

CONTACT:

SYNOVA Zac Tsai
Tel: +44 (0)20 3475 7658

Tim Ashlin
Tel: +44 (0)20 3475 7668